JPMorgan analyst Richard Vosser upgraded Sanofi (SNY) to Overweight from Neutral with a price target of EUR 105, down from EUR 110. The firm sees positive risk/reward into the company’s data readouts as it believes little pipeline value is being priced into the shares. Sanofi is undervalued even in the unlikely event of these assets being worth zero, the analyst tells investors in a research note. JPMorgan says Sanofi is trading at a 20% discount to the sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology Pipeline
- Sanofi’s Phase 3 Study on Tolebrutinib: A Potential Game-Changer for Multiple Sclerosis
- Sanofi’s SAR443579 Study Terminated: Implications for Hematological Cancer Treatment
- Sanofi’s Promising Phase 2 Study on Crohn’s Disease Treatment
- Sanofi’s Teplizumab Study in Japan: A Potential Game-Changer for Type 1 Diabetes